Track topics on Twitter Track topics that are important to you
SAN CLEMENTE, CA -- (Marketwired) -- 07/24/15 -- Micro Imaging Technology, Inc. (OTCQB: MMTC) announced that, through its collaboration with Northern Michigan University (NMU), it has developed a testing protocol that allows for detection of pathogen species from liquid cultures. Dr. Josh S. Sharp, Ph.D., assistant professor at the NMU Department of Biology in Marquette, Michigan, has been spearheading the collaboration between MIT and NMU since October of 2013. He is researching clinical applications of the MIT 1000 System, particularly the pathogens Staphylococcus aureus (S. aureus) and Methicillin Resistant S. aureus (MRSA). "Many of the current agar plate based identification methods require 16-24 hours of growth before identifications can be made," said Dr. Sharp. "Our work with MIT and its rapid laser-based identification system, the MIT 1000, has effectively eliminated the need for that time-consuming step and reduced the time required for pathogen sample preparation and identification to 4-6 hours given a sufficient starting inoculum. This new protocol allows for detection of Staphylococcus species from liquid cultures and has provided important groundwork to facilitate rapid enrichment of target bacteria for identification using the MIT 1000."
"The MIT 1000 has already proven to be one of, if not the fastest and least expensive method for pathogen testing out there," said Jeff Nunez, President of MIT. "This recent innovation in capturing target bacteria, eliminating the need for agar plate culturing, should prove to be a highly significant leap forward for the MIT 1000 in both clinical and food safety applications."
About: Northern Michigan University
Northern Michigan University, located in Marquette, Michigan, is a dynamic four-year, public, coeducational university that has grown its reputation based on its award-winning leadership programs, cutting-edge technology initiatives and nationally recognized academic programs. The university's fastest growing academic areas are clinical science, biology, and the geographical and environmental sciences. Northern Michigan has a population of about 9,000 undergraduate and graduate students. It offers 180 degree programs, including 18 graduate programs.
About: Micro Imaging Technology, Inc.
Micro Imaging Technology, Inc. is a California-based public company that is also registered to do business under the name Micro Identification Technologies. MIT has developed and patented the MIT 1000, a stand-alone, rapid, optically-based, software driven system that can identify pathogenic bacteria and complete an identification test, after culturing, in three (3) minutes (average) at the lowest cost per test when compared to any other conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process requires only clean filtered water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3.5 billion, which is expected to surpass $4.7 billion by this year according to BCC Research. In addition, the recently passed "New" U.S. Food Safety Bill is expected to further accelerate the current annual growth rate of 6.6 percent.
In June 2009, the AOAC Research Institute (AOAC RI) awarded the Company Performance Tested Methods SM (PTM) certification for the rapid identification of Listeria. The AOAC RI provides an independent third party evaluation and expert reviews of methods and will award PTM certification to methods that demonstrate performance levels equivalent or better than other certified bacteria identifying methods. The MIT System underwent hundreds of individual tests, including ruggedness and accuracy, to earn AOAC RI's certification for the identification of Listeria.
You can find more information about our company and about Micro Identification Technologies. Please visit our newly enhanced website at www.micro-identification.com.
This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission, reference MMTC: www.sec.gov.NEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...